Abstract
Background Osteoporosis is a major disease that affects the quality of life of middle-aged and old people, so it is very important to find efficient and safe drugs to treat osteoporosis. The purpose of this study was to investigate the therapeutic effect of naringin on postmenopausal osteoporosis in ovariectomized (OVX) rats. Methods Chinese biomedical databases, CNKI, PubMed, EMBASE, and Wan Fang were searched for articles from inception to March 2020. Two independent researchers screened articles according to inclusion criteria. RevMan 5.3 was used for data analysis. Results Ten studies were included in the systematic review. The bone mineral density (BMD) significantly increased after naringin treatment (weighted mean difference, 0.06; 95% CI, 0.03–0.09; P < 0.01). There was no significant increase in BMD after estrogen treatment compared with naringin (weighted mean difference, 0.00; 95% CI, −0.00 to 0.01; P = 0.06). The trabecular bone volume (BV/TV) (weighted mean difference, 2.09; 95% CI, 1.85–2.34; P < 0.01) and trabecular thickness (Tb.Th) (weighted mean difference, 6.65; 95% CI, 6.55–6.74; P < 0.01) significantly increased after using naringin. Conclusions Naringin had been shown to promote bone formation in OVX rats. However, the mechanism of naringin needs more research to confirm.
Highlights
Osteoporosis is a major disease that affects the quality of life of middle-aged and old people, so it is very important to find efficient and safe drugs to treat osteoporosis. e purpose of this study was to investigate the therapeutic effect of naringin on postmenopausal osteoporosis in ovariectomized (OVX) rats
The references of selected articles were used as a supplement. ere were no language restrictions. is review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting criteria [15]. e Stroke erapy Academic Industry Roundtable (STAIR) list was used for methodological quality assessment in our study [16]
A thorough review of the remaining 47 articles was carried out, of which 37 articles were excluded. e reason for exclusion was the absence of bone mineral density (BMD) measurements, being clinic reports, or studies only in vitro
Summary
Osteoporosis is a major disease that affects the quality of life of middle-aged and old people, so it is very important to find efficient and safe drugs to treat osteoporosis. e purpose of this study was to investigate the therapeutic effect of naringin on postmenopausal osteoporosis in ovariectomized (OVX) rats. E bone mineral density (BMD) significantly increased after naringin treatment (weighted mean difference, 0.06; 95% CI, 0.03–0.09; P < 0.01). Ere was no significant increase in BMD after estrogen treatment compared with naringin (weighted mean difference, 0.00; 95% CI, −0.00 to 0.01; P 0.06). E pathological characteristics of osteoporosis include bone mineral density (BMD) reduction, bone microstructure deterioration, and matrix protein degradation, resulting in an increased bone fragility and risk of fracture [2]. It reduces the quality of life of the elderly, and causes huge financial burden to patients’ families and society. In an effort to discover new drugs that treat osteoporosis effectively, much focus has been put on the pursuit of natural-based products because of their availability, cost-effectiveness, and biological activity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
